Company intelligence / Profile preview
Sutro Biopharma, Inc.
South San Francisco, California, United Statessutrobio.com ↗
- Ownership
- Public · STRO
- Employees
- ~500
- Development stage
- Phase 2
01
Overview
Sutro Biopharma has advanced a robust early-stage pipeline of novel antibody-drug conjugates and immunotherapies. Its lead asset, luveltamab tazevibulin ("luvelta", STRO–002), targets folate receptor alpha for ovarian/endometrial cancer and has reached registrational clinical studies. Other assets include STRO–001 for B-cell malignancies and several partnered programs with Merck/MSD and Astellas. The company’s proprietary cell-free protein synthesis platforms enable rapid discovery of optimized biologics with improved therapeutic profiles. Multiple candidates are in clinical trials or preclinical development.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)Bispecific antibodiesCytokine-based immuno-oncology therapiesVaccines
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
Merck/MSD – collaboration on MK‐1484 IL‐2 agonist programAstellas Pharma – collaboration on Immunostimulatory ADCs (“iADCs”)Celgene/BMS – prior licensing/collaboration agreement but not acquired by Celgene/BMS
04
Financials
- Market cap
- $172.5M
- Total revenue
- $9.8M
- Enterprise value
- $19M
Beyond the preview
Go deeper on Sutro Biopharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sutro Biopharma, Inc..